Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host … Read more
Cynata Therapeutics Limited (CYYNF) - Net Assets
Latest net assets as of June 2025: $5.98 Million USD
Based on the latest financial reports, Cynata Therapeutics Limited (CYYNF) has net assets worth $5.98 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.20 Million) and total liabilities ($1.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.98 Million |
| % of Total Assets | 83.1% |
| Annual Growth Rate | 3.17% |
| 5-Year Change | -78.92% |
| 10-Year Change | -30.31% |
| Growth Volatility | 121.32 |
Cynata Therapeutics Limited - Net Assets Trend (2007–2025)
This chart illustrates how Cynata Therapeutics Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cynata Therapeutics Limited (2007–2025)
The table below shows the annual net assets of Cynata Therapeutics Limited from 2007 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $5.98 Million | -17.12% |
| 2024-06-30 | $7.22 Million | -56.87% |
| 2023-06-30 | $16.73 Million | -30.16% |
| 2022-06-30 | $23.96 Million | -15.55% |
| 2021-06-30 | $28.37 Million | +68.98% |
| 2020-06-30 | $16.79 Million | +53.04% |
| 2019-06-30 | $10.97 Million | -28.70% |
| 2018-06-30 | $15.39 Million | +10.98% |
| 2017-06-30 | $13.86 Million | +61.53% |
| 2016-06-30 | $8.58 Million | -1.91% |
| 2015-06-30 | $8.75 Million | -11.21% |
| 2014-06-30 | $9.85 Million | +499.85% |
| 2013-06-30 | $1.64 Million | +92.43% |
| 2012-06-30 | $853.75K | -12.16% |
| 2011-06-30 | $971.93K | +4.28% |
| 2010-06-30 | $932.00K | -3.12% |
| 2009-06-30 | $961.98K | -56.48% |
| 2008-06-30 | $2.21 Million | -35.17% |
| 2007-06-30 | $3.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cynata Therapeutics Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8989377100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $89.52 Million | 1496.54% |
| Other Comprehensive Income | $8.17 Million | 136.61% |
| Total Equity | $5.98 Million | 100.00% |
Cynata Therapeutics Limited Competitors by Market Cap
The table below lists competitors of Cynata Therapeutics Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Crown Crafts Inc
NASDAQ:CRWS
|
$25.18 Million |
|
Truong Thanh Energy and Real Estate JSC
VN:TEG
|
$25.18 Million |
|
Globon Co. Ltd
KQ:019660
|
$25.19 Million |
|
NHOA S.A
PINK:ENGPF
|
$25.19 Million |
|
Echomarketing Co.Ltd
KQ:230360
|
$25.16 Million |
|
WEBSTEP ASA NK 1
F:5ZF
|
$25.16 Million |
|
Redefine Properties Ltd
JSE:RDF
|
$25.15 Million |
|
Infrea AB
ST:INFREA
|
$25.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cynata Therapeutics Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,217,235 to 5,981,735, a change of -1,235,500 (-17.1%).
- Net loss of 9,390,586 reduced equity.
- Share repurchases of 522,264 reduced equity.
- New share issuances of 8,136,935 increased equity.
- Other comprehensive income increased equity by 260,475.
- Other factors increased equity by 279,940.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.39 Million | -156.99% |
| Share Repurchases | $522.26K | -8.73% |
| Share Issuances | $8.14 Million | +136.03% |
| Other Comprehensive Income | $260.48K | +4.35% |
| Other Changes | $279.94K | +4.68% |
| Total Change | $- | -17.12% |
Book Value vs Market Value Analysis
This analysis compares Cynata Therapeutics Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.69x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.14x to 4.69x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-06-30 | $0.99 | $0.14 | x |
| 2008-06-30 | $0.65 | $0.14 | x |
| 2009-06-30 | $0.28 | $0.14 | x |
| 2010-06-30 | $0.24 | $0.14 | x |
| 2011-06-30 | $0.19 | $0.14 | x |
| 2012-06-30 | $0.09 | $0.14 | x |
| 2013-06-30 | $0.07 | $0.14 | x |
| 2014-06-30 | $0.22 | $0.14 | x |
| 2015-06-30 | $0.14 | $0.14 | x |
| 2016-06-30 | $0.12 | $0.14 | x |
| 2017-06-30 | $0.17 | $0.14 | x |
| 2018-06-30 | $0.17 | $0.14 | x |
| 2019-06-30 | $0.11 | $0.14 | x |
| 2020-06-30 | $0.16 | $0.14 | x |
| 2021-06-30 | $0.22 | $0.14 | x |
| 2022-06-30 | $0.17 | $0.14 | x |
| 2023-06-30 | $0.12 | $0.14 | x |
| 2024-06-30 | $0.04 | $0.14 | x |
| 2025-06-30 | $0.03 | $0.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cynata Therapeutics Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -156.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -498.14%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.20x
- Recent ROE (-156.99%) is below the historical average (-90.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -67.25% | -424.10% | 0.15x | 1.05x | $-1.71 Million |
| 2009 | -114.48% | 0.00% | 0.00x | 1.48x | $-1.20 Million |
| 2010 | -227.05% | -1858.22% | 0.09x | 1.34x | $-2.21 Million |
| 2011 | -263.91% | -1150.54% | 0.18x | 1.25x | $-2.66 Million |
| 2012 | -180.65% | -949.39% | 0.16x | 1.19x | $-1.63 Million |
| 2013 | -55.74% | -2696.09% | 0.02x | 1.09x | $-1.08 Million |
| 2014 | -30.85% | -12130.51% | 0.00x | 1.01x | $-4.03 Million |
| 2015 | -42.42% | -1299.82% | 0.03x | 1.04x | $-4.59 Million |
| 2016 | -57.55% | -449.16% | 0.12x | 1.05x | $-5.80 Million |
| 2017 | -32.84% | -260.37% | 0.12x | 1.03x | $-5.94 Million |
| 2018 | -29.68% | -332.05% | 0.09x | 1.05x | $-6.10 Million |
| 2019 | -77.22% | -647.44% | 0.11x | 1.12x | $-9.57 Million |
| 2020 | -21.67% | -51.90% | 0.40x | 1.04x | $-5.32 Million |
| 2021 | -27.10% | -497.38% | 0.05x | 1.06x | $-10.53 Million |
| 2022 | -22.73% | -70.08% | 0.29x | 1.11x | $-7.84 Million |
| 2023 | -85.32% | -863.05% | 0.09x | 1.14x | $-15.95 Million |
| 2024 | -135.02% | -420.82% | 0.28x | 1.16x | $-10.47 Million |
| 2025 | -156.99% | -498.14% | 0.26x | 1.20x | $-9.99 Million |
Industry Comparison
This section compares Cynata Therapeutics Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cynata Therapeutics Limited (CYYNF) | $5.98 Million | -67.25% | 0.20x | $25.18 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |